 | 
 | |
October 25, 2007
Nile Therapeutics to Present at the Rodman & Renshaw 9th Annual Healthcare
BERKELEY, CALIFORNIA, Oct. 25, 2007 - Nile Therapeutics, Inc. (OTC Bulletin Board: NILT.OB) will present at the Rodman & Renshaw 9th Annual Healthcare Conference at 10:30 AM EST on Wednesday, November 7th at The Palace Hotel in New York.
Mr. Peter Strumph, Chief Executive Officer of Nile will provide an overview of Nile and an update on its clinical development programs, including data from Nile's recently completed Phase I study for its lead compound, CD-NP, a novel chimeric peptide for the treatment of heart failure.
The presentation will be webcast live and can be accessed by visiting the Investor Relations section of Nile's website at http://www.nilethera.com/conference.html. The webcast will be archived for 90 days. Additional information regarding the Rodman & Renshaw Healthcare Conference can be accessed at http://www.rodmanandrenshaw.com/conferences?id=6.
About Nile Therapeutics
Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel chimeric peptide in Phase I studies for the treatment of heart failure, and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties. A key component of the Company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at www.nilethera.com.
Contact:
Daron Evans
Chief Financial Officer
Nile Therapeutics, Inc.
510-281-7700
info@nilethera.com
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including the "Risk Factors" section of our Form 8-K filed with the Securities and Exchange Commission on September 21, 2007. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
| |
|
